Published in J Immunol on September 15, 2007
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol (2008) 2.50
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol (2010) 1.70
Discovering biological progression underlying microarray samples. PLoS Comput Biol (2011) 1.65
Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells. Cancer Cell (2014) 1.60
Human haematopoietic stem cell lineage commitment is a continuous process. Nat Cell Biol (2017) 1.52
SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One (2013) 1.25
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A (2010) 1.24
Early B cell factor: Regulator of B lineage specification and commitment. Semin Immunol (2008) 1.07
Air1 zinc knuckles 4 and 5 and a conserved IWRXY motif are critical for the function and integrity of the Trf4/5-Air1/2-Mtr4 polyadenylation (TRAMP) RNA quality control complex. J Biol Chem (2011) 1.00
Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum (2010) 0.97
The developmental regulator protein Gon4l associates with protein YY1, co-repressor Sin3a, and histone deacetylase 1 and mediates transcriptional repression. J Biol Chem (2011) 0.91
The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage. PLoS One (2010) 0.90
Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines. Biomed Rep (2012) 0.85
IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells. Blood (2011) 0.83
Early B lymphocyte development: Similarities and differences in human and mouse. World J Stem Cells (2014) 0.83
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia (2016) 0.83
Conditional meta-analysis stratifying on detailed HLA genotypes identifies a novel type 1 diabetes locus around TCF19 in the MHC. Hum Genet (2010) 0.82
Zinc fingers and homeoboxes family in human diseases. Cancer Gene Ther (2015) 0.81
Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell. Sci Rep (2015) 0.81
5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype. Leukemia (2012) 0.81
A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun (2015) 0.80
Transcriptional profiling of mRNAs and microRNAs in human bone marrow precursor B cells identifies subset- and age-specific variations. PLoS One (2013) 0.79
Genome-wide DNA methylation analysis in precursor B-cells. Epigenetics (2014) 0.79
Aberrantly Expressed OTX Homeobox Genes Deregulate B-Cell Differentiation in Hodgkin Lymphoma. PLoS One (2015) 0.79
Calprotectin (S100A8/S100A9) and myeloperoxidase: co-regulators of formation of reactive oxygen species. Toxins (Basel) (2010) 0.79
A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells. Stem Cell Reports (2014) 0.78
Integrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia. Epigenetics (2015) 0.77
Overlap Chronic Placental Inflammation Is Associated with a Unique Gene Expression Pattern. PLoS One (2015) 0.77
Bone marrow transcriptome and epigenome profiles of equine common variable immunodeficiency patients unveil block of B lymphocyte differentiation. Clin Immunol (2015) 0.77
Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in man. BMC Immunol (2014) 0.76
Promoter methylation and expression levels of selected hematopoietic genes in pediatric B-cell acute lymphoblastic leukemia. Blood Res (2015) 0.76
Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis. Mol Biol Int (2016) 0.75
Global gene regulation during activation of immunoglobulin class switching in human B cells. Sci Rep (2016) 0.75
Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma. Oncotarget (2015) 0.75
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med (2016) 0.75
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 5.10
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res (2005) 4.84
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Characteristics of 454 pyrosequencing data--enabling realistic simulation with flowsim. Bioinformatics (2010) 4.08
The genome sequence of Atlantic cod reveals a unique immune system. Nature (2011) 3.99
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
Aggressive lymphomas. N Engl J Med (2010) 3.86
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 3.59
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev (2006) 3.49
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2008) 3.19
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03
Identifying functional modules in protein-protein interaction networks: an integrated exact approach. Bioinformatics (2008) 3.00
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol (2004) 2.90
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
New feature subset selection procedures for classification of expression profiles. Genome Biol (2002) 2.54
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood (2010) 2.49
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell (2007) 2.46
Pathogenesis of human B cell lymphomas. Annu Rev Immunol (2012) 2.44
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol (2011) 2.38
Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol (2002) 2.37
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol (2007) 2.35
Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol (2004) 2.35
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med (2013) 2.31
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol (2010) 2.30
The EMBRACE web service collection. Nucleic Acids Res (2010) 2.26